Scott Tagawa, MD, MS, FACP, comments on treatment and management strategies in metastatic castration-resistant prostate cancer (CRPC), and reviews recent data on the VISION trial of Lu 177 vipivotide tetraxetan.
EP. 7: Efficacy Data from the VISION Trial of Lu 177 Vipivotide TetraxetanApril 15th 2022
Scott Tagawa, MD, MS, FACP, reviews key efficacy data from the VISION trial of Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (CRPC).
EP. 10: Potential Use of Lu 177 Vipivotide Tetraxetan in Non-VISION Prostate Cancer SettingsApril 15th 2022
Scott Tagawa, MD, MS, FACP, discusses other prostate cancer settings besides metastatic CRPC where Lu 177 vipivotide tetraxetan could potentially be useful, and touches on ongoing clinical trials in these settings.
EP. 11: Potential Barriers and Challenges to Use of Radiotherapy in Prostate CancerApril 15th 2022
An overview of the barriers and challenges that patients, caregivers, clinicians, and other healthcare personnel may face when radiation-based therapies are used for treatment of prostate cancer.
EP. 12: Future Directions in Prostate Cancer and Clinical Pearls for CliniciansApril 15th 2022
Scott Tagawa, MD, MS, FACP wraps up by discussing how he envisions the future of prostate cancer and offers advice to community oncologists treating patients with the disease.